June 29, 2020
Sarah Temkin, MD, board-certified gynecologic oncologist, and Don Dizon, MD, oncologist specializing in women’s cancers, discuss an ongoing Phase III trial that examines the use of selinexor for the treatment of endometrial cancer, and highlight what they hope to see for the future of care.
Vergote I, Hamilton EP, Romero I, et al. SIENDO/ENGOT-EN5: A randomized phase III trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer. J Clin Oncol 38: 2020 (suppl; abstr TPS6105). doi: 10.1200/JCO.2020.38.15_suppl.TPS6105